Standard of care

Heart Failure Monitoring Technology Doubles Sensitivity for Predicting Events While Minimizing False Alerts Versus Standard of Care

Retrieved on: 
Wednesday, March 6, 2024

SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.

Key Points: 
  • SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Bodyport Inc., a virtual care company focused on heart failure, today announced data from a late-breaking presentation showing its FDA-cleared, non-invasive, biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events as compared to the weight-based standard of care.
  • It demonstrated this using the same monitoring routine patients already follow in weighing themselves daily and concurrently minimized false alerts for care teams, generating nearly 40 percent fewer overall alerts.
  • Over the course of the study, the Congestion Index correctly predicted 48 of 69 heart failure events (70%), demonstrating significantly higher sensitivity (p
  • In addition to demonstrating greater sensitivity in detecting heart failure events, the Congestion Index did so with a lower alert rate, generating only 2.58 alerts per patient-year compared to the 4.18 produced by the standard of care.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

National Alliance of Healthcare Purchaser Coalitions Releases Employer Recommendations to Address Obesity Coverage

Retrieved on: 
Tuesday, February 27, 2024

WASHINGTON, Feb. 27, 2024 /PRNewswire/ -- Obesity affects more than 40% of the US population with far-reaching consequences for not only individuals but employers grappling with the negative impact to workforce health. With the recent introduction of innovative new therapies to treat obesity, the standard of care is rapidly evolving. To help employers and other purchasers make informed coverage decisions about comprehensive, holistic approaches to obesity care, the nonprofit National Alliance of Healthcare Purchaser Coalitions (National Alliance) released guidance today from its National Obesity Advisory Council made up of employers, business coalitions, and medical experts.

Key Points: 
  • To help employers and other purchasers make informed coverage decisions about comprehensive, holistic approaches to obesity care, the nonprofit National Alliance of Healthcare Purchaser Coalitions (National Alliance) released guidance today from its National Obesity Advisory Council made up of employers, business coalitions, and medical experts.
  • The coverage guidance and full report, Addressing Obesity through Holistic Design for Affordability and Sustainability, can be downloaded here .
  • "As the science of obesity evolves, employers will have better resources and tools to address the needs of their employees," said Margaret Rehayem, National Alliance vice president.
  • The National Obesity Advisory Council is an experienced group of leaders from National Alliance member coalitions, clinicians and other industry experts deeply involved in assessing and making recommendations about obesity coverage and treatment best practices.

Carbon and Desktop Health Join Forces in Consortium with Diverse and Trusted Pillars of the Oral Health Industry to Advance the Adoption of Innovative Digital Dentistry Applications

Retrieved on: 
Thursday, February 22, 2024

REDWOOD CITY, Calif., Feb. 22, 2024 /PRNewswire/ -- Carbon, a leading product development and manufacturing technology company, today announced that it is partnering with Heartland Dental, Desktop Health™, an industry-leading dental technology innovator, and Dr. Robert Mongrain. The consortium's goal is to unite their perspectives to focus on enhancing patient outcomes by creating streamlined workflows for digitally designed removable denture appliances.

Key Points: 
  • The consortium's goal is to unite their perspectives to focus on enhancing patient outcomes by creating streamlined workflows for digitally designed removable denture appliances.
  • The dental industry is undergoing a historic and exciting digital transformation as it leads industries of all types into the digital era.
  • Technological advancements, particularly in the additive manufacturing space, are enabling more efficient and predictable dental restorations for greater patient outcomes and care.
  • Collaboration like this within the dental community can more effectively leverage industry-leading innovations for the highest standard of patient care.

Photocure ASA: Results for the fourth quarter of 2023

Retrieved on: 
Wednesday, February 21, 2024

Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.

Key Points: 
  • Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.
  • "Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and we delivered EBITDA of NOK 29.9 million.
  • Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange.
  • At the end of the fourth quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 352, an increase of 17% or 51 towers since the fourth quarter of 2022.

Photocure ASA: Results for the fourth quarter of 2023

Retrieved on: 
Wednesday, February 21, 2024

Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.

Key Points: 
  • Total revenues increased 37% in the fourth quarter of 2023 compared to Q4 2022, including a milestone payment from Asieris related to the license agreement for Cevira®.
  • "Hexvix/Cysview revenue increased 20% year-over-year in the fourth quarter, and we delivered EBITDA of NOK 29.9 million.
  • Photocure reported total group revenues of NOK 142.5 million in the fourth quarter of 2023 (NOK 104.2 million), and EBITDA* of NOK 29.9 million (NOK -16.9 million), driven by a combination of unit volume growth, price increases and a benefit from foreign exchange.
  • At the end of the fourth quarter of 2023, the installed base of rigid blue light cystoscopy (BLC®) systems in the U.S. was 352, an increase of 17% or 51 towers since the fourth quarter of 2022.

Pioneering Online Veterinary Assistant and Veterinary Assistant Scribe Training Programs Launch to Enhance Pet Care Services

Retrieved on: 
Monday, February 19, 2024

The Veterinary Assistant and Veterinary Assistant Scribe Online Training Programs, developed by industry experts and seasoned veterinarians, offer a flexible and accessible learning experience.

Key Points: 
  • The Veterinary Assistant and Veterinary Assistant Scribe Online Training Programs, developed by industry experts and seasoned veterinarians, offer a flexible and accessible learning experience.
  • The Veterinary Assistant and Veterinary Assistant Scribe Online Training Programs, developed by industry experts and seasoned veterinarians, prepare learners for a new career in the field of veterinary medicine.
  • "We are thrilled to introduce our Veterinary Assistant and Veterinary Assistant Scribe Online Training Programs, a pioneering initiative that bridges the gap between education and practice in the veterinary industry," said Peter Reilly, President of AHDPG.
  • Enrollment for the Veterinary Assistant and Veterinary Assist Scribe Online Training Programs is now open.

FDA Approves First Medication to Treat Severe Frostbite

Retrieved on: 
Wednesday, February 14, 2024

SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

Key Points: 
  • SILVER SPRING, Md., Feb. 14, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.
  • Frostbite can occur in several stages, ranging from mild frostbite that does not require medical intervention and does not cause permanent skin damage, to severe frostbite when both the skin and underlying tissue are frozen and blood flow is stopped, sometimes requiring amputation.
  • Iloprost's efficacy in treating severe frostbite was primarily established in an open-label, controlled trial that randomized 47 adults with severe frostbite, who all received aspirin by vein and standard of care, into one of three treatment groups.
  • The two other groups received other medications that are unapproved for frostbite, given with iloprost (Group 2) or without iloprost (Group 3).

STARmed to Accelerate Global Market Entry of EUSRA and ELRA Products through Olympus

Retrieved on: 
Wednesday, February 14, 2024

EUSRA and ELRA products had been distributed by Taewoong Medical Co., Ltd., a Korean manufacturer of gastrointestinal medical devices.

Key Points: 
  • EUSRA and ELRA products had been distributed by Taewoong Medical Co., Ltd., a Korean manufacturer of gastrointestinal medical devices.
  • With the completion of Olympus' acquisition of Taewoong Medical, Olympus has become a global distribution partner of STARmed 's EUSRA and ELSA products.
  • This will enable STARmed to accelerate its global market expansion and provide better healthcare to patients around the world.
  • "We recognize STARmed's EUSRA and ELRA products as well-received and high-quality products," said Mike Callaghan, Vice President, General Manager of GI EndoTherapy at Olympus.

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.